Literature DB >> 8996148

Fertility after chemotherapy for testicular germ cell cancers.

H Lampe1, A Horwich, A Norman, J Nicholls, D P Dearnaley.   

Abstract

PURPOSE: To analyze the probability of recovery of spermatogenesis after orchidectomy and cisplatin-based chemotherapy (CT) for testicular germ cell cancer. PATIENTS AND METHODS: One hundred seventy-eight patients treated between 1979 and 1991 were selected by the requirement of sperm count both pre-CT and post-CT. Counts were classified as normospermic (NS) if more than 10 x 10(6)/mL, oligospermic (OS) if 1 to 9 x 10(6)/mL, and azoospermic (AS) if less than 1 x 10(6)/mL. The median follow-up time after CT before sperm analysis was 30 months.
RESULTS: Analysis of 170 patients whose spermatogenesis was reassessed at least 1 year after CT showed that of 89 patients whose pre-CT counts were NS, the post-CT count was NS in 64%, OS in 16%, and AS in 20%. There was clear evidence for continued recovery beyond 1 year; the probability of spermatogenesis increased to 48% by 2 years and 80% by 5 years. There was a significantly higher probability of recovery to OS and NS count levels in the 54 patients treated with carboplatin-rather than cisplatin-based therapy. There was an independent and similar effect of normal pre-CT count. There was a reduced probability to recover to OS in the 26 patients treated with more than four cycles of CT. A prognostic model identified three groups with 25%, 45%, and 82% probabilities of recovering spermatogenesis by 2 years after CT.
CONCLUSION: Analysis of pre-CT sperm count together with details of planned treatment can be used to predict recovery of spermatogenesis following germ cell CT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8996148     DOI: 10.1200/JCO.1997.15.1.239

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  50 in total

Review 1.  Regular review: Managing testicular cancer.

Authors:  D Dearnaley; R Huddart; A Horwich
Journal:  BMJ       Date:  2001-06-30

Review 2.  The genetic and phenotypic basis of infertility in men with pediatric urologic disorders.

Authors:  Michael H Hsieh; Adam Hollander; Dolores J Lamb; Paul J Turek
Journal:  Urology       Date:  2010-05-07       Impact factor: 2.649

Review 3.  Comparative tolerability of chemotherapy regimens for germ cell cancer.

Authors:  S Culine; J P Droz
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 4.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Impact of the chemotherapy cocktail used to treat testicular cancer on the gene expression profile of germ cells from male Brown-Norway rats.

Authors:  Geraldine Delbès; Donovan Chan; Pirjo Pakarinen; Jacquetta M Trasler; Barbara F Hales; Bernard Robaire
Journal:  Biol Reprod       Date:  2008-11-05       Impact factor: 4.285

6.  Follicle-stimulating hormone enhances recovery from low-dose doxorubicin-induced spermatogenic disorders in mice.

Authors:  Jun Hagiuda; Hiromichi Ishikawa; Satoru Kaneko; Masako Okazaki; Mototsugu Oya; Ken Nakagawa
Journal:  J Assist Reprod Genet       Date:  2015-04-16       Impact factor: 3.412

Review 7.  Preservation of fertility of adult male cancer patients treated with chemotherapy.

Authors:  Koji Kawai; Hiroyuki Nishiyama
Journal:  Int J Clin Oncol       Date:  2018-10-23       Impact factor: 3.402

8.  Preservation of sperm of cancer patients: extent of use and pregnancy outcome in a tertiary infertility center.

Authors:  Amnon Botchan; Shiri Karpol; Ofer Lehavi; Gedalia Paz; Sandra E Kleiman; Leah Yogev; Haim Yavetz; Ron Hauser
Journal:  Asian J Androl       Date:  2013-03-25       Impact factor: 3.285

Review 9.  Testicular cancer: a prototypic tumor of young adults.

Authors:  Brandon Hayes-Lattin; Craig R Nichols
Journal:  Semin Oncol       Date:  2009-10       Impact factor: 4.929

Review 10.  [Management of chemotherapy side effects and their long-term sequelae].

Authors:  Isabella M Zraik; Yasmine Heß-Busch
Journal:  Urologe A       Date:  2021-06-29       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.